These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 1714636)

  • 1. Suppression of splenic accessory cell function in mice exposed to gallium arsenide.
    Sikorski EE; Burns LA; McCoy KL; Stern M; Munson AE
    Toxicol Appl Pharmacol; 1991 Aug; 110(1):143-56. PubMed ID: 1714636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Splenic cell targets in gallium arsenide-induced suppression of the primary antibody response.
    Sikorski EE; Burns LA; Stern ML; Luster MI; Munson AE
    Toxicol Appl Pharmacol; 1991 Aug; 110(1):129-42. PubMed ID: 1871769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gallium arsenide exposure impairs processing of particulate antigen by macrophages: modification of the antigen reverses the functional defect.
    Hartmann CB; McCoy KL
    Life Sci; 2004 Jun; 75(4):485-98. PubMed ID: 15147834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for arsenic as the immunosuppressive component of gallium arsenide.
    Burns LA; Sikorski EE; Saady JJ; Munson AE
    Toxicol Appl Pharmacol; 1991 Aug; 110(1):157-69. PubMed ID: 1651571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gallium arsenide selectively suppresses antigen processing by splenic macrophages for CD4+ T cell activation.
    Lewis TA; Munson AE; McCoy KL
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1244-51. PubMed ID: 8819508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotoxicity of the semiconductor gallium arsenide in female B6C3F1 mice.
    Sikorski EE; McCay JA; White KL; Bradley SG; Munson AE
    Fundam Appl Toxicol; 1989 Nov; 13(4):843-58. PubMed ID: 2695379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gallium arsenide exposure impairs splenic B cell accessory function.
    Gondre-Lewis TA; Hartmann CB; Caffrey RE; McCoy KL
    Int Immunopharmacol; 2003 Mar; 3(3):403-15. PubMed ID: 12639818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gallium arsenide selectively inhibits T cell proliferation and alters expression of CD25 (IL-2R/p55).
    Burns LA; Munson AE
    J Pharmacol Exp Ther; 1993 Apr; 265(1):178-86. PubMed ID: 8097242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A functional characterization of macrophage alterations in casein-treated B6C3F1 mice.
    Kaminski NE; Holsapple MP
    Immunopharmacology; 1992; 24(3):229-40. PubMed ID: 1478855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gallium arsenide differentially affects processing of phagolysosomal targeted antigen by macrophages.
    Lewis TA; Hartmann CB; McCoy KL
    J Leukoc Biol; 1998 Mar; 63(3):321-30. PubMed ID: 9500519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gallium arsenide augments antigen processing by peritoneal macrophages for CD4+ helper T cell stimulation.
    Hartmann CB; McCoy KL
    Toxicol Appl Pharmacol; 1996 Dec; 141(2):365-72. PubMed ID: 8975760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct exposure to gallium arsenide upregulates costimulatory activity of murine macrophages.
    Caffrey-Nolan RE; McCoy KL
    Toxicol Appl Pharmacol; 1998 Aug; 151(2):330-9. PubMed ID: 9707509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of gallium arsenide-induced suppression of the antibody-forming cell response by vehicle supernatants. I. Pharmacokinetics after in vitro and in vivo exposure.
    Burns LA; Munson AE
    J Pharmacol Exp Ther; 1993 Apr; 265(1):144-9. PubMed ID: 8386233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gallium arsenide modulates proteolytic cathepsin activities and antigen processing by macrophages.
    Lewis TA; Hartmann CB; McCoy KL
    J Immunol; 1998 Sep; 161(5):2151-7. PubMed ID: 9725206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of benzo(a)pyrene-induced modulation of antigen presentation.
    Myers MJ; Schook LB; Bick PH
    J Pharmacol Exp Ther; 1987 Aug; 242(2):399-404. PubMed ID: 3497259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of gallium arsenide-induced suppression of the antibody response by a mixed disulfide metabolite of meso-2,3-dimercaptosuccinic acid.
    Burns LA; Butterworth LF; Munson AE
    J Pharmacol Exp Ther; 1993 Feb; 264(2):695-700. PubMed ID: 8382280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-4 synthesis by in vivo primed keyhole limpet hemocyanin-specific CD4+ T cells. I. Influence of antigen concentration and antigen-presenting cell type.
    DeKruyff RH; Fang Y; Umetsu DT
    J Immunol; 1992 Dec; 149(11):3468-76. PubMed ID: 1358971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of gallium arsenide-induced suppression of the antibody-forming cell response by vehicle supernatants. II. Nature and identification of reversing factors.
    Burns LA; Munson AE
    J Pharmacol Exp Ther; 1993 Apr; 265(1):150-8. PubMed ID: 8474002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of macrophages as modulators but not as autonomous accessory cells in the proliferative response of immune T cells to soluble antigen.
    Kawai J; Inaba K; Komatsubara S; Hirayama Y; Naito K; Muramatsu S
    Cell Immunol; 1987 Oct; 109(1):1-11. PubMed ID: 3498537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gallium arsenide-induced increase in serum corticosterone is not responsible for suppression of the IgM antibody response.
    Burns LA; Spriggs TL; Fuchs BA; Munson AE
    J Pharmacol Exp Ther; 1994 Feb; 268(2):740-6. PubMed ID: 7509391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.